Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma

References

• American Cancer SocietyCancer Facts & Figures 2017AtlantaACS2017
   Google Scholar
• LiPWongYNArmstrongKSurvival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy erasCancer Med20165216918126645975
   PubMed Web of Science ®Google Scholar
• RiniBISmallEJBiology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinomaJ Clin Oncol20052351028104315534359
   PubMed Web of Science ®Google Scholar
• ClarkPEThe role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapyKidney Int200976993994519657325
   PubMed Web of Science ®Google Scholar
• NiuGChenXVascular endothelial growth factor as an anti-angiogenic target for cancer therapyCurr Drug Targets20101181000101720426765
   PubMed Web of Science ®Google Scholar
• RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247
   PubMed Web of Science ®Google Scholar
• ChoueiriTKEscudierBPowlesTCabozantinib versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191814182326406150
   PubMed Web of Science ®Google Scholar
• ChoueiriTKEscudierBPowlesTCabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialLancet Oncol201617791792727279544
   PubMed Web of Science ®Google Scholar
• MotzerRJonaschEAgarwalNNCCN guidelines: kidney cancer – version 22017 Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdfAccessed February 6, 2017
   Google Scholar
• LjungbergBBensalahKBexAEuropean Association of Urology guidelines: renal cell carcinoma2016 http://uroweb.org/guideline/renal-cell-carcinomaAccessed February 20, 2017
   Google Scholar
• EscudierBPortaCSchmidingerMRenal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201627Suppl 5v58v6827664262
   PubMed Web of Science ®Google Scholar
• Cabometyx^® (cabozantinib) [prescribing information]South San FranciscoExelixis, Inc2016
   Google Scholar
• Cabometyx^® (cabozantinib) [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004163/WC500214071.pdfAccessed March 3, 2017
   Google Scholar
• KoochekpourSJeffersMWangPHThe von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cellsMol Cell Biol19991995902591210454537
   PubMed Web of Science ®Google Scholar
• NakaigawaNYaoMBabaMInactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinomaCancer Res20066673699370516585196
   PubMed Web of Science ®Google Scholar
• RankinEBFuhKCCastelliniLDirect regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and METProc Natl Acad Sci U S A201411137133731337825187556
   PubMed Web of Science ®Google Scholar
• YuHLiuRMaBAxl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinomaBr J Cancer2015113461662526180925
   PubMedGoogle Scholar
• BenvenutiSComoglioPMThe MET receptor tyrosine kinase in invasion and metastasisJ Cell Physiol2007213231632517607709
   PubMed Web of Science ®Google Scholar
• YakesFMChenJTanJCabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growthMol Cancer Ther201110122298230821926191
   PubMed Web of Science ®Google Scholar
• ZhouLLiuXDSunMTargeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinomaOncogene201635212687269726364599
   PubMed Web of Science ®Google Scholar
• Cometriq^® (cabozantinib) [prescribing information]South San FranciscoExelixis, Inc2012
   Google Scholar
• LacySAMilesDRNguyenLTClinical pharmacokinetics and pharmacodynamics of cabozantinibClin Pharmacokinet201756547749127734291
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyCHMP assessment report: Cabometyx2016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004163/WC500214070.pdfAccessed January 20, 2017
   Google Scholar
• EisenTSternbergCNRobertCTargeted therapies for renal cell carcinoma: review of adverse event management strategiesJ Natl Cancer Inst201210429311322235142
   PubMed Web of Science ®Google Scholar
• CohenRBOudardSAntiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicitiesInvest New Drugs20123052066207922327313
   PubMed Web of Science ®Google Scholar
• RavaudAEditorial comment to Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaInt J Urol201219980522651229
   PubMed Web of Science ®Google Scholar
• TeradaTNodaSInuiKManagement of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitorsPharmacol Ther201515212513425976912
   PubMed Web of Science ®Google Scholar
• RuizJNBelumVRCreelPCohnAEwerMLacoutureMECurrent practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologistsClin Genitourin Cancer201412534134725035283
   PubMedGoogle Scholar
• MilesDJumbeNLLacySNguyenLPopulation pharmacokinetic model of cabozantinib in patients with medullary thyroid carcinoma and its application to an exposure-response analysisClin Pharmacokinet20165519310526149244
   PubMed Web of Science ®Google Scholar
• ExelixisCABOMETYX dosing and administration guide2016 Available from: https://hcp.cabometyx.com/downloads/CABOMETYXDosingandAdministrationGuide.pdfAccessed February 16, 2017
   Google Scholar
• National Cancer InstituteCommon Terminology Criteria for Adverse Events (CTCAE). Version 4.03WashingtonUS Department of Health and Human Services2009
   Google Scholar
• HurriaADotanEBaumgartnerJNCCN guidelines: older adult oncology – version 22016 Available from: https://www.nccn.org/professionals/physician_gls/pdf/senior.pdfAccessed February 22, 2017
   Google Scholar
• RavaudATreatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapiesOncologist201116Suppl 2324421346038
   PubMed Web of Science ®Google Scholar
• KollmannsbergerCBjarnasonGBurnettPSunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicitiesOncologist201116554355321490127
   PubMed Web of Science ®Google Scholar
• NguyenLHollandJMamelokREvaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjectsJ Clin Pharmacol201555111293130225907407
   PubMed Web of Science ®Google Scholar
• ChoueiriTKEscudierBPowlesTCabozantinib versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191814182326406150
   PubMed Web of Science ®Google Scholar
• LenihanDJKoweyPROverview and management of cardiac adverse events associated with tyrosine kinase inhibitorsOncologist201318890090823918069
   PubMedGoogle Scholar
• UhligKPatelKIpSKitsiosGDBalkEMSelf-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysisAnn Intern Med2013159318519423922064
   PubMed Web of Science ®Google Scholar
• PickeringTGWhiteWBGilesTDWhen and how to use self (home) and ambulatory blood pressure monitoringJ Am Soc Hypertens201042566120400049
   PubMed Web of Science ®Google Scholar
• JamesPAOparilSCarterBL2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)JAMA2014311550752024352797
   PubMed Web of Science ®Google Scholar
• MaitlandMLBakrisGLBlackHRInitial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitorsJ Natl Cancer Inst2010102959660420351338
   PubMedGoogle Scholar
• LarochellePKollmannsbergerCFeldmanRDHypertension management in patients with renal cell cancer treated with anti-angiogenic agentsCurr Oncol201219420220822876146
   PubMedGoogle Scholar
• ZhouSFXueCCYuXQLiCWangGClinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoringTher Drug Monit200729668771018043468
   PubMed Web of Science ®Google Scholar
• IvanyiPBeutelGDrewesNTherapy of treatment-related hypertension in metastatic renal-cell cancer patients receiving sunitinibClin Genitourin Cancer201715228029027863831
   PubMedGoogle Scholar
• ChoYTChanCCCabozantinib-induced hand-foot skin reaction with subungual splinter hemorrhages and hypertension: a possible association with inhibition of the vascular endothelial growth factor signaling pathwayEur J Dermatol201323227427523518371
   PubMed Web of Science ®Google Scholar
• EsfandiariNHHesseltineEAVisual vignette: cabozantinib-induced hand-foot syndromeEndocr Pract2013196107124014004
   PubMedGoogle Scholar
• BelumVRSerna-TamayoCWuSLacoutureMEIncidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysisClin Exp Dermatol201641181526009777
   PubMed Web of Science ®Google Scholar
• ZuoRCApoloABDiGiovannaJJCutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinibJAMA Dermatol2015151217017725427282
   PubMed Web of Science ®Google Scholar
• JayaramAZafeiriouZde BonoJSCabozantinib: getting under the skin of cutaneous toxicityJAMA Oncol20151453553626181263
   PubMedGoogle Scholar
• PolovichPOLeFebvreKBSide effects of cancer therapyPolovichPOOlsenMLeFebvreKBChemotherapy and Biotherapy Guidelines and Recommendations for Practice4th edPittsburghOncology Nursing Society2016171435
   Google Scholar
• EdmondsKHullDSpencer-ShawAStrategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task groupEur J Oncol Nurs201216217218421641280
   PubMed Web of Science ®Google Scholar
• Oncology Nursing SocietyPEP rating system overview2016 Available from: https://www.ons.org/practice-resources/pepAccessed February 16, 2017
   Google Scholar
• BowenJMMechanisms of TKI-induced diarrhea in cancer patientsCurr Opin Support Palliat Care20137216216723399616
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyNutrition for the person with cancer during treatment2017 Available from: https://www.cancer.org/treatment/survivorship-during-and-after-treatment/staying-active/nutrition/nutrition-during-treatment.htmlAccessed February 16, 2017
   Google Scholar
• RyanKPSymptom control and side effectsWhen Tumor is the Rumor and Cancer is the AnswerBloomington (IN)AuthorHouse2013181209
   Google Scholar
• Cancer Research UKTips on coping with diarrhoea Available from: http://www.cancerresearchuk.org/about-cancer/coping/physically/bowel-problems/types/diarrhoea/tips-coping-diarrhoeaAccessed August 24, 2017
   Google Scholar
• McCreaJBMajumdarAKGoldbergMREffects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisoloneClin Pharmacol Ther2003741172412844131
   PubMed Web of Science ®Google Scholar
• HeskethPJGrunbergSMGrallaRJThe oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin: the Aprepitant Protocol 052 Study GroupJ Clin Oncol200321224112411914559886
   PubMed Web of Science ®Google Scholar
• EttingerDBergerMAstonJNCCN guidelines: antiemesis – version 22016 Available from: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdfAccessed February 16, 2017
   Google Scholar
• Cesamet^® (nabilone) [prescribing information]Somerset (NJ)Meda Pharmaceuticals Inc2013
   Google Scholar
• KatzPOGersonLBVelaMFGuidelines for the diagnosis and management of gastroesophageal reflux diseaseAm J Gastroenterol2013108330832923419381
   PubMed Web of Science ®Google Scholar
• CreelPAOptimizing patient adherence to targeted therapies in renal cell carcinomaClin J Oncol Nurs201418669470025427704
   PubMedGoogle Scholar
• TsaiSImportance of lean body mass in the oncologic patientNutr Clin Pract201227559359822898746
   PubMed Web of Science ®Google Scholar
• LevyMSmithTAlvarez-PerezANCCN guidelines: palliative care – version 12016 Available from: https://www.nccn.org/professionals/physician_gls/pdf/palliative.pdfAccessed February 17, 2017
   Google Scholar
• AnandDEscalanteCPOngoing screening and treatment to potentially reduce tyrosine kinase inhibitor-related fatigue in renal cell carcinomaJ Pain Symptom Manage201550110811725701692
   PubMed Web of Science ®Google Scholar
• GeorgeGCIwuanyanwuECAndersonKOSleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trialsCancer2016122213401340927412379
   PubMed Web of Science ®Google Scholar
• BergerAMooneyKBanerjeeCNCCN guidelines: cancer-related fatigue – version 12016 Available from: https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdfAccessed February 17, 2017
   Google Scholar
• MitchellSAHoffmanAJClarkJCPutting evidence into practice: an update of evidence-based interventions for cancer-related fatigue during and following treatmentClin J Oncol Nurs201418Suppl385825427608
   PubMed Web of Science ®Google Scholar
• Al-MajidSWatersHThe biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exerciseBiol Res Nurs200810172018705151
   PubMedGoogle Scholar
• MintonORichardsonASharpeMHotopfMStonePDrug therapy for the management of cancer-related fatigueCochrane Database Syst Rev20107CD00670420614448
   PubMed Web of Science ®Google Scholar
• Provigil^® (modafinil) [prescribing information]Frazer (PA)Cephalon, Inc1998
   Google Scholar
• YuanAKurtzSLBarysauskasCMPilotteAPWagnerAJTreisterNSOral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitorsOral Oncol201551111026103326403941
   PubMedGoogle Scholar
• PetersonDEBoers-DoetsCBBensadounRJHerrstedtJManagement of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-upAnn Oncol201526Suppl 5v139v15126142468
   PubMedGoogle Scholar
• BlevinsDPDaduRHuMAerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancerThyroid201424591892224635127
   PubMed Web of Science ®Google Scholar
• BurgerRABradyMFBookmanMARisk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol201432121210121724637999
   PubMed Web of Science ®Google Scholar
• ShinagareABHowardSAKrajewskiKMZukotynskiKAJagannathanJPRamaiyaNHPneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its managementAJR Am J Roentgenol201219961259126523169717
   PubMedGoogle Scholar
• WeitzmanSPCabanillasMEThe treatment landscape in thyroid cancer: a focus on cabozantinibCancer Manag Res2015726527826316818
   PubMed Web of Science ®Google Scholar
• McLellanBCiardielloFLacoutureMESegaertSvan CutsemERegorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and managementAnn Oncol201526102017202626034039
   PubMed Web of Science ®Google Scholar
• AlexandrescuDTVaillantJGDasanuCAEffect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitorsClin Exp Dermatol2007321717417034418
   PubMedGoogle Scholar